Qiagen


Qiagen’s potential bidders

13/12/19 -"As Siemens Healthineers has said that it is not interested in buying Qiagen, Roche could emerge as one of the bidders for the Dutch firm from the European side. While Thermo Fisher seems as a ..."

Pages
62
Language
English
Published on
13/12/19
You may also be interested by these reports :
22/03/24
We have included the announced 1,000-to-1 reverse stock split into our number of shares, following the effectiveness of the share consolidation and ...

22/03/24
We have maintained our assumption and the company’s plan of a €300m capital increase to be completed in 2024, but with an expected subscription price ...

21/03/24
Bastide’s half-year turnover and EBITDA both saw decent yoy growth despite heavier payroll costs, while the underlying operating margin moderately ...

18/03/24
DiaSorin’s 2023 results were in line with street expectations, however the profitability guidance miss disappointed investors. Healthy performance by ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO